Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19875312 | 1.00 | MME (0.69) | MMEACE | |
| SCHEMBL11970038 | 1.00 | MME (0.69) | MMEACE | |
| SCHEMBL12480732 | 1.00 | MME (0.69) | MMEACE | |
| SCHEMBL11969569 | 1.00 | MME (0.69) | MMEACE | |
| SCHEMBL19888572 | 0.92 | MME (0.60) | MMEACE | |
| SCHEMBL18411187 | 0.92 | MME (0.60) | MMEACE | |
| SCHEMBL18410999 | 0.92 | MME (0.60) | MMEACE | |
| SCHEMBL12481787 | 0.92 | MME (0.68) | MMEACE | |
| SCHEMBL11969803 | 0.92 | MME (0.68) | MMEACE | |
| SCHEMBL11969787 | 0.91 | MME (0.69) | MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10130642-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-20 | — | — | US | claimed |
| US-20180050052-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-22 | — | — | US | claimed |
| EP-2882716-A1 | NEPRILYSIN INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014025891-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| EP-2675795-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | Theravance, Inc. (US) | 2013-12-25 | — | — | EP | disclosed |
| WO-2012112742-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10130642-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885 |
| US-20180050052-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.